home / stock / fosi / fosi quote
Last: | $1 |
---|---|
Change Percent: | 0.0% |
Open: | $1 |
Close: | $1 |
High: | $1 |
Low: | $1 |
Volume: | 200 |
Last Trade Date Time: | 09/11/2020 04:53:59 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1 | $1 | $1 | $1 | $1 | 200 | 09-11-2020 |
$0.8 | $0.8 | $0.8 | $0.8 | $0.8 | 944 | 09-07-2020 |
$0.8 | $0.8 | $0.8 | $0.8 | $0.8 | 944 | 09-04-2020 |
$1.02 | $1.02 | $1.02 | $1.02 | $1.02 | 280 | 09-03-2020 |
$1.04 | $1.2 | $1.04 | $1.2 | $0.8 | 3,125 | 09-02-2020 |
$1.2001 | $1.25 | $1.2001 | $1.25 | $1.2001 | 2,800 | 09-01-2020 |
$1.7 | $1.2501 | $1.7 | $1.7 | $1.2501 | 571 | 08-14-2020 |
$1.69 | $1.25 | $1.69 | $1.69 | $1.25 | 200 | 08-13-2020 |
$1.7 | $1.7 | $1.7 | $1.7 | $1.7 | 150 | 08-11-2020 |
$1.5 | $1.53 | $1.5 | $1.53 | $1.5 | 2,220 | 08-10-2020 |
$1.75 | $1.52 | $1.75 | $1.75 | $1.52 | 291 | 08-07-2020 |
$1.75 | $1.52 | $1.75 | $1.75 | $1.52 | 394 | 08-06-2020 |
$1.75 | $1.75 | $1.75 | $1.75 | $1.75 | 100 | 07-29-2020 |
$1.5 | $1.8 | $1.5 | $1.8 | $1.5 | 670 | 07-28-2020 |
$1.8 | $2.23 | $1.8 | $2.23 | $1.05 | 3,088 | 07-27-2020 |
$2 | $1.95 | $2 | $2.02 | $1.95 | 4,510 | 07-23-2020 |
$1.95 | $1.95 | $1.95 | $1.95 | $1.95 | 228 | 07-22-2020 |
$1.975 | $1.95 | $1.975 | $2 | $1.95 | 400 | 07-21-2020 |
$1.9 | $1.9 | $1.9 | $1.9 | $1.9 | 1,110 | 07-20-2020 |
$1.9 | $1.56 | $1.9 | $1.9 | $1.56 | 713 | 07-17-2020 |
News, Short Squeeze, Breakout and More Instantly...
TRICCAR Company Name:
FOSI Stock Symbol:
OTCMKTS Market:
LAS VEGAS , July 13, 2020 /PRNewswire/ -- TRICCAR, Inc. (OTC: FOSI), a bioceutical development and marketing firm, announced that it has completed an agreement for an investment of $18,594,692 via private placement in the public entity from Antonomastic Investment Holdings, L...
LAS VEGAS , June 10, 2020 /PRNewswire/ -- As the United States and world continue to struggle with the ongoing effects of the COVID-19 pandemic, TRICCAR, Inc. (OTC: FOSI), announces the results of a double-blind placebo-controlled study of AVL™, its proprietary immune-support ant...